ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 18.7
(-1.32%)
TWD 18.7
(-1.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.72 Billion TWD | -1.59% |
| 2022 | 11.91 Billion TWD | 1.88% |
| 2021 | 11.69 Billion TWD | -1.31% |
| 2020 | 11.84 Billion TWD | 1.47% |
| 2019 | 11.67 Billion TWD | -7.07% |
| 2018 | 12.56 Billion TWD | -1.09% |
| 2017 | 12.7 Billion TWD | -0.64% |
| 2016 | 12.78 Billion TWD | 4.59% |
| 2015 | 12.22 Billion TWD | 7.47% |
| 2014 | 11.37 Billion TWD | -0.98% |
| 2013 | 11.48 Billion TWD | 11.36% |
| 2012 | 10.31 Billion TWD | 8.78% |
| 2011 | 9.48 Billion TWD | 29.9% |
| 2010 | 7.29 Billion TWD | 25.31% |
| 2009 | 5.82 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 11.97 Billion TWD | 2.16% |
| 2024 Q2 | 11.99 Billion TWD | 0.17% |
| 2023 Q1 | 11.97 Billion TWD | 0.51% |
| 2023 Q3 | 11.56 Billion TWD | -2.71% |
| 2023 Q4 | 11.72 Billion TWD | 1.34% |
| 2023 Q2 | 11.88 Billion TWD | -0.69% |
| 2023 FY | 11.72 Billion TWD | -1.59% |
| 2022 Q4 | 11.91 Billion TWD | 1.46% |
| 2022 Q2 | 12.03 Billion TWD | 0.79% |
| 2022 Q1 | 11.94 Billion TWD | 2.13% |
| 2022 FY | 11.91 Billion TWD | 1.88% |
| 2022 Q3 | 11.73 Billion TWD | -2.46% |
| 2021 Q2 | 12.07 Billion TWD | -0.82% |
| 2021 Q4 | 11.69 Billion TWD | 2.12% |
| 2021 Q1 | 12.17 Billion TWD | 2.8% |
| 2021 FY | 11.69 Billion TWD | -1.31% |
| 2021 Q3 | 11.44 Billion TWD | -5.21% |
| 2020 Q4 | 11.84 Billion TWD | -1.28% |
| 2020 Q2 | 12.1 Billion TWD | 3.92% |
| 2020 Q1 | 11.65 Billion TWD | -0.19% |
| 2020 FY | 11.84 Billion TWD | 1.47% |
| 2020 Q3 | 12 Billion TWD | -0.89% |
| 2019 Q3 | 11.72 Billion TWD | -13.81% |
| 2019 Q4 | 11.67 Billion TWD | -0.4% |
| 2019 Q2 | 13.6 Billion TWD | -0.94% |
| 2019 Q1 | 13.72 Billion TWD | 9.28% |
| 2019 FY | 11.67 Billion TWD | -7.07% |
| 2018 Q4 | 12.56 Billion TWD | -1.91% |
| 2018 FY | 12.56 Billion TWD | -1.09% |
| 2018 Q1 | 13.15 Billion TWD | 3.57% |
| 2018 Q2 | 13.25 Billion TWD | 0.76% |
| 2018 Q3 | 12.8 Billion TWD | -3.38% |
| 2017 Q1 | 12.85 Billion TWD | 0.55% |
| 2017 FY | 12.7 Billion TWD | -0.64% |
| 2017 Q4 | 12.7 Billion TWD | -1.31% |
| 2017 Q3 | 12.86 Billion TWD | -0.08% |
| 2017 Q2 | 12.88 Billion TWD | 0.21% |
| 2016 FY | 12.78 Billion TWD | 4.59% |
| 2016 Q3 | 12.5 Billion TWD | -0.29% |
| 2016 Q2 | 12.54 Billion TWD | 0.43% |
| 2016 Q1 | 12.49 Billion TWD | 2.2% |
| 2016 Q4 | 12.78 Billion TWD | 2.19% |
| 2015 Q1 | 11.57 Billion TWD | 1.75% |
| 2015 FY | 12.22 Billion TWD | 7.47% |
| 2015 Q4 | 12.22 Billion TWD | 1.89% |
| 2015 Q3 | 11.99 Billion TWD | 1.01% |
| 2015 Q2 | 11.87 Billion TWD | 2.62% |
| 2014 Q3 | 11.24 Billion TWD | -4.69% |
| 2014 Q4 | 11.37 Billion TWD | 1.16% |
| 2014 FY | 11.37 Billion TWD | -0.98% |
| 2014 Q2 | 11.79 Billion TWD | -1.95% |
| 2014 Q1 | 12.02 Billion TWD | 4.75% |
| 2013 Q3 | 11.12 Billion TWD | -4.98% |
| 2013 FY | 11.48 Billion TWD | 11.36% |
| 2013 Q1 | 11.03 Billion TWD | 7.02% |
| 2013 Q2 | 11.7 Billion TWD | 6.03% |
| 2013 Q4 | 11.48 Billion TWD | 3.27% |
| 2012 Q4 | 10.31 Billion TWD | 8.04% |
| 2012 FY | 10.31 Billion TWD | 8.78% |
| 2012 Q2 | 9.82 Billion TWD | 1.39% |
| 2012 Q1 | 9.68 Billion TWD | 2.2% |
| 2012 Q3 | 9.54 Billion TWD | -2.83% |
| 2011 Q3 | 8.96 Billion TWD | 17.59% |
| 2011 Q4 | 9.48 Billion TWD | 5.74% |
| 2011 Q2 | 7.62 Billion TWD | 0.0% |
| 2011 FY | 9.48 Billion TWD | 29.9% |
| 2010 FY | 7.29 Billion TWD | 25.31% |
| 2010 Q4 | 7.29 Billion TWD | 0.0% |
| 2009 FY | 5.82 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Grape King Bio Ltd | 15.51 Billion TWD | 24.435% |
| Standard Chem & Pharm CO., LTD. | 11.18 Billion TWD | -4.762% |
| Maywufa Company Ltd. | 2.83 Billion TWD | -313.887% |
| Lotus Pharmaceutical Co., Ltd. | 32.99 Billion TWD | 64.471% |
| LIWANLI Innovation Co., Ltd. | 834.17 Million TWD | -1305.174% |
| YungShin Global Holding Corporation | 11.51 Billion TWD | -1.817% |
| PhytoHealth Corporation | 2.35 Billion TWD | -398.682% |
| SCI Pharmtech, Inc. | 6.69 Billion TWD | -75.191% |
| Formosa Laboratories, Inc. | 13.63 Billion TWD | 14.041% |
| PharmaEssentia Corporation | 27.26 Billion TWD | 57.015% |
| Bora Pharmaceuticals Co., LTD. | 25.05 Billion TWD | 53.211% |